A study employing a DSS-induced IBD murine model demonstrated that treatment with human gingiva-derived MSCs markedly suppressed the frequency of splenic NK 1.1+, CD11b+, and CD4+ T cells (179). This evidence concerns the gene CD4 and inflammatory bowel disease.